CSafe Global, a provider of active and passive, temperature-controlled containers for gene and cellular solutions for the transport of life-saving drugs, announced on Tuesday that it has entered into a partnership with BioNTech for the thermal shipments of Pfizer-BioNTech COVID-19 vaccines from Germany.

CSafe Global will act as the solution provider for thermal shipments of Pfizer-BioNTech COVID-19 vaccines from the BioNTech plant in Germany.

The company's bespoke thermo container maintains a temperature of -70 ° C for a minimum of 240 hours ensuring that the vaccine arrives safely anywhere in the world. The bespoke container features a double-walled VIP (Vacuum Insulated Panel) technology of the highest level, a customizable load box with trays for the product vials, as well as an integrated handle that simplifies packing and unpacking operations.

According to the company, the thermal tests exceeded all expectations and, in all tests, the packaging went well beyond the minimum storage time of 240 hours. The container maintains the desired temperature indefinitely with the addition of dry ice as needed.

Based on BioNTech's proprietary technology, the Pfizer-BioNTech COVID-19 vaccine (BNT162b2) was developed by both BioNTech and Pfizer. BioNTech holds marketing authorization in the EU and authorizations for emergency use - or equivalent - in the US (together with Pfizer), the UK, Canada and other countries before of the planned application for a final marketing authorisation.